Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Revenue | $4.39M | $4.94M |
| Revenue growth | — | 12.5% |
| Gross profit | -$112K | -$204K |
| Gross margin | -2.6% | -4.1% |
| Operating income | -$13.7M | -$13.3M |
| Operating margin | -312.3% | -268.4% |
| Net income | -$21.1M | -$27.0M |
| Net margin | -479.5% | -546.6% |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$11.9M | -$15.7M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $96.0K | $7.45M |
| Total assets | $12.1M | $22.5M |
| Total liabilities | $35.8M | $18.8M |
| Shareholders' equity | -$44.0M | $3.79M |
| Retained earnings | -$49.8M | -$76.8M |
| Shares (wtd avg diluted) | 7.94M | 36.2M |
Every figure is extracted from Picard Medical, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.